Last updated on November 2017

FOURIER - Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk

Other Details:

The primary hypothesis is that additional LDL-C lowering with Evolocumab (AMG 145) when used in addition to other treatment for dyslipidemia is well tolerated and decreases the risk of cardiovascular death, myocardial infarction, hospitalization for unstable angina, stroke, or coronary revascularization in subjects with clinically evident cardiovascular disease.

Contact Investigators or Research Sites near you

Start Over

Cheryl Langer, RN / Kimberly ...

Holy Cross Jim Moran Heart and Vascular Research Institute
Fort Lauderdale, FL USA